---
type: earnings-call
company: "Cigna Group"
ticker: CI
quarter: Q3
fiscal_year: 2024
source: Yahoo Finance
---

## Summary
Cigna Group reported a strong third quarter, driven by Evernorth's performance and cost-saving initiatives, with revenue reaching $63.7 billion and adjusted EPS of $7.51. The company has repurchased $5.7 billion of stock year-to-date and expects full-year 2024 adjusted EPS of at least $28.40, representing over 13% year-over-year growth, while also anticipating continued strategic investments and navigating headwinds like lower net investment income and potentially constrained overhead after the sale of the Medicare Advantage business.

## Guidance
{'Full Year 2024 Adjusted EPS Outlook': 'At least $28.40, representing over 13% year-over-year growth.'}

## Strategic Initiatives
['Expansion of biosimilar offerings (HUMIRA)', 'Continued strategic investments across portfolio', 'Focusing on GLP-1 affordability through programs like EnCircleRx']

## Risks
['Lower net investment income due to the absence of the VillageMD dividend', 'Constrained overhead from the sale of the Medicare Advantage business', 'Challenged Medicare Advantage market due to elevated medical costs and changes in star ratings', 'Elevated commercial trends driving up costs']

---
## Transcript
Total Revenue:$63.7 billion for the third quarter.

Adjusted Earnings Per Share (EPS):$7.51 for the third quarter.

Shareholders' Net Income:$739 million or $2.63 per share for the third quarter.

Special Item Charges:$162 million or $0.58 per share after-tax net special item charges for the third quarter.

Evernorth Revenue:$52.5 billion for the third quarter.

Evernorth Pretax Adjusted Earnings:$1.9 billion, a 9% increase for the third quarter.

Specialty and Care Services Revenue:$23.8 billion for the third quarter.

Specialty and Care Services Adjusted Earnings:$825 million for the third quarter.

Cigna Healthcare Revenue:$13.3 billion for the third quarter.

Cigna Healthcare Pretax Adjusted Earnings:$1.2 billion for the third quarter.

Medical Care Ratio:82.8% for the third quarter.

Share Repurchase:$5.7 billion year-to-date, including $715 million in October.

Full Year 2024 Adjusted EPS Outlook:At least $28.40, representing over 13% year-over-year growth.

Warning! GuruFocus has detected 6 Warning Signs with SWI.

Release Date: October 31, 2024

For the complete transcript of the earnings call, please refer to thefull earnings call transcript.

The Cigna Group (NYSE:CI) reported strong third-quarter financial results with total revenue of $63.7 billion and adjusted earnings per share of $7.51.

Evernorth Health Services, a growth platform of The Cigna Group (NYSE:CI), delivered strong top and bottom line contributions, driven by market-leading innovation and affordability initiatives.

The company is on track to deliver full-year adjusted earnings per share of at least $28.40 in 2024, representing more than 13% year-over-year growth.

The Cigna Group (NYSE:CI) has successfully expanded its biosimilar offerings, with significant adoption of HUMIRA biosimilars, contributing to cost savings for patients and clients.

The company has repurchased approximately $5.7 billion of its common stock year-to-date, demonstrating confidence in its business strength and sustainable growth.

The Cigna Group (NYSE:CI) recorded a noncash, after-tax net realized investment loss of $1 billion related to VillageMD, impacting shareholders' net income.

The company faces headwinds from lower net investment income due to the absence of the VillageMD dividend.

There is a potential for constrained overhead from the sale of the Medicare Advantage business, which the company will need to mitigate over time.

The Medicare Advantage market is currently challenged due to elevated medical costs and significant changes in star ratings, contributing to operational disruptions.

The company anticipates continued strategic investments across its portfolio, which may impact short-term financial performance.

Q: With elevated commercial trends this year, are you assuming similar trends for 2025, and are employers pushing back on this approach?A: Brian Evanko, CFO, explained that Cigna expects cost trends to remain elevated above historical levels in 2025. They are pricing for rate increases greater than those in 2024 to preserve margin levels, despite a competitive but rational market environment.

Q: Can you clarify your capital deployment strategy in light of market rumors and share repurchases?A: David Cordani, CEO, stated that while detailed guidance for 2025 will be provided later, Cigna has been actively repurchasing shares in 2024 and plans to continue in the fourth quarter. The company has repurchased about $24 billion of stock over the last four years, leveraging its asset-light portfolio.

Q: What is driving the significant growth in the EnCircleRx program, and what are the future expectations?A: Eric Palmer, CEO of Evernorth Health Services, noted that there is strong client interest in managing GLP-1 affordability. The EnCircleRx program, which targets the right patient population with clinical support, has grown rapidly to almost 8 million lives, indicating significant demand and effectiveness.

Q: How is the 2025 PBM selling season shaping up, and are there changes in contract economics due to biosimilars?A: Eric Palmer highlighted that Evernorth had a good 2025 selling season with retention rates in the mid- to high 90s percent range. While there is interest in discussing service and financing arrangements, there are no substantial changes in what clients are purchasing.

Q: Can you provide more detail on the headwinds and tailwinds for 2025, and how confident are you in achieving at least 10% EPS growth?A: Brian Evanko outlined several tailwinds, including biosimilar adoption and EPS accretion from Medicare sale proceeds, and headwinds like the absence of the VillageMD dividend. Despite these factors, Cigna is confident in achieving at least 10% EPS growth in 2025.

For the complete transcript of the earnings call, please refer to thefull earnings call transcript.

This article first appeared onGuruFocus.
